VNU cancels $7 billion acquisition of IMS, cites shareholders

Share this article:

Dutch publisher VNU has terminated its $7 billion plan to take over IMS Health, both companies confirmed.
"Several of VNU's major shareholders have made it clear, for a variety of reasons, they did not want to pursue any large merger at this time," said IMS CEO/president David Carlucci in a statement.
"While we regret that the merger with VNU will not happen, our business is strong." VNU CEO Rob van den Bergh said, "Having heard the views of our shareholders, it became clear that it
would not be possible for us to proceed with the proposed merger." In a statement announcing the cancellation of the deal, van den Bergh added that he planned to step down from his CEO post. It was unclear at press time whether his resignation was directly related to the dissolution of the merger.
VNU has agreed to reimburse IMS $15 million for its actual out-ofpocket costs related to merger planning, and an additional $45 million should VNU be acquired in the next 12 months. For its part, IMS has agreed to return the $15 million payment to VNU if IMS is acquired in
the next 12 months. Since the deal was announced in July, VNU shareholders reacted negatively to the merger plan. Nearly half of VNU shareholders said they wouldn't vote for the deal under any circumstances, essentially dooming the deal before it could reach a full vote.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...